Huijuan Kong

ORCID: 0000-0003-0535-2438 · 9 papers in corpus
observational 2025
Frontiers in endocrinology ·doi:10.3389/fendo.2025.1574123

BACKGROUND: Endometrial thickness (EMT) has been confirmed to be associated with pregnancy outcomes after in vitro fertilization/intracytoplasmic sperm injection-embryo transfer (IVF/ICSI-ET), but studies on its relationship with neonatal o…

observational 2025
Scientific reports ·doi:10.1038/s41598-025-20150-2

The relationship between blastocyst morphological quality and the risk of congenital malformations in assisted reproductive technology (ART) remains poorly understood, limiting clinical decision-making for embryo selection. We conducted a r…

observational 2025
Scientific reports ·doi:10.1038/s41598-025-86656-x

It has been debated whether endometriosis (EMS) adversely affects oocyte quality, potentially leading to a higher incidence of genetically unbalanced embryos or other egg factors that affect the developmental potential. In this study, we ex…

observational 2025
Frontiers in endocrinology ·doi:10.3389/fendo.2025.1637587

OBJECTIVE: To evaluate the impact of endometrial thickness (EMT) variations on clinical outcomes in two distinct ovarian stimulation protocols: the early-follicular long-acting GnRH agonist protocol and the midluteal short-acting GnRH agoni…

observational 2024
Scientific reports ·doi:10.1038/s41598-024-82783-z

This study aimed to develop and validate a predictive model for failure to collect oocytes in the Patient-Oriented Strategies Encompassing Individualized Oocyte Number (POSEIDON) Groups 3 and 4 during their first in vitro fertilization/intr…

observational 2019
Frontiers in endocrinology ·doi:10.3389/fendo.2019.00834

Background: Polycystic ovary syndrome (PCOS) patients have a better ovarian reserve and age-related improvement in endocrine disturbances than non-PCOS patients. The effects of age on in vitro fertilization (IVF) treatment outcomes associat…

observational 2019
·doi:10.12659/msm.916447

BACKGROUND: Patients with endometriosis (EMs) are routinely advised to take GnRH-a for 3–6 months to improve the internal reproductive environment, but this may not be necessary. MATERIAL/METHODS: This retrospective study examined the effec…

observational 2019
Medical science monitor : international medical journal of experimental and clinical research ·doi:10.12659/MSM.916447

BACKGROUND Patients with endometriosis (EMs) are routinely advised to take GnRH-a for 3-6 months to improve the internal reproductive environment, but this may not be necessary. MATERIAL AND METHODS This retrospective study examined the eff…

rct 2018
Reproductive health ·doi:10.1186/s12978-018-0639-8

BACKGROUND: Endometriosis is the major cause of progressive pelvic pain and subfertility. Up to 50% of reproductive-age women suffer from pelvic pain. Endometriosis is a classic indication for IVF. Compared with women whose inability to pro…